{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lundstrom A"],"funding":["STROKE-Riksförbundet","Foundation for Coagulation Research KI","Stockholms Läns Landsting"],"pagination":["708-719"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7340656"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(4)"],"pubmed_abstract":["Platelet microvesicles (PMV) have previously been found elevated in acute ischemic stroke (IS) and could be biomarkers for risk of recurrence. PMV surface antigens such as P-selectin and phosphatidylserine (PS) reflect platelet activation and procoagulance. Tissue factor-positive microvesicles (TF<sup>+</sup>MV) are considered procoagulant, in particular if co-expressing PS. We enumerated MV subpopulations with these surface antigens in a cohort of 211 patients with primarily non-cardioembolic IS or transient ischemic attack (TIA) and investigated their association with long-term outcome. MV concentrations were determined by flow cytometry in the acute and convalescent phase. Primary outcome was a composite of fatal and non-fatal recurrent IS or myocardial infarction. Secondary outcomes were recurrent IS and all-cause mortality. Outcome events were obtained from Swedish registers during a follow-up of 1100 patient years. Concentrations of PS-positive and PS-negative MV populations were elevated in patients compared with healthy controls in both the acute and convalescent phase. PS<sup>+</sup>TF<sup>+</sup>PMV displayed pronounced elevations, median fold change 77 in the acute phase (p < 0.0001) but were not associated with outcome, neither were PS<sup>+</sup>P-selectin<sup>+</sup>PMV. The only subpopulation positively associated with primary outcome was PS<sup>-</sup>TF<sup>+</sup>PMV, with adjusted hazard ratio of 1.86 (1.04-3.31, p = 0.036) by Cox regression. Unexpectedly, several MV subpopulations tended to be associated with reduced risk of poor long-term outcome. Our results suggest that PS<sup>+</sup>TF<sup>+</sup>PMV may be a promising marker for cerebral ischemia, and that the in vivo generation of PS<sup>-</sup>MV after IS/TIA warrants further study. Future MV studies should ideally enumerate PS<sup>+</sup> and PS<sup>-</sup>MV subpopulations separately."],"journal":["Translational stroke research"],"pubmed_title":["Prognostic Value of Circulating Microvesicle Subpopulations in Ischemic Stroke and TIA."],"pmcid":["PMC7340656"],"funding_grant_id":["Regional agreement on Clinical Research","NA"],"pubmed_authors":["Rooth E","Thalin C","Wallen H","Henriksson P","Gigante B","von Arbin M","Lundstrom A","Mobarrez F","Laska AC"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic Value of Circulating Microvesicle Subpopulations in Ischemic Stroke and TIA.","description":"Platelet microvesicles (PMV) have previously been found elevated in acute ischemic stroke (IS) and could be biomarkers for risk of recurrence. PMV surface antigens such as P-selectin and phosphatidylserine (PS) reflect platelet activation and procoagulance. Tissue factor-positive microvesicles (TF<sup>+</sup>MV) are considered procoagulant, in particular if co-expressing PS. We enumerated MV subpopulations with these surface antigens in a cohort of 211 patients with primarily non-cardioembolic IS or transient ischemic attack (TIA) and investigated their association with long-term outcome. MV concentrations were determined by flow cytometry in the acute and convalescent phase. Primary outcome was a composite of fatal and non-fatal recurrent IS or myocardial infarction. Secondary outcomes were recurrent IS and all-cause mortality. Outcome events were obtained from Swedish registers during a follow-up of 1100 patient years. Concentrations of PS-positive and PS-negative MV populations were elevated in patients compared with healthy controls in both the acute and convalescent phase. PS<sup>+</sup>TF<sup>+</sup>PMV displayed pronounced elevations, median fold change 77 in the acute phase (p < 0.0001) but were not associated with outcome, neither were PS<sup>+</sup>P-selectin<sup>+</sup>PMV. The only subpopulation positively associated with primary outcome was PS<sup>-</sup>TF<sup>+</sup>PMV, with adjusted hazard ratio of 1.86 (1.04-3.31, p = 0.036) by Cox regression. Unexpectedly, several MV subpopulations tended to be associated with reduced risk of poor long-term outcome. Our results suggest that PS<sup>+</sup>TF<sup>+</sup>PMV may be a promising marker for cerebral ischemia, and that the in vivo generation of PS<sup>-</sup>MV after IS/TIA warrants further study. Future MV studies should ideally enumerate PS<sup>+</sup> and PS<sup>-</sup>MV subpopulations separately.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-26T08:13:19.693Z","creation":"2025-04-06T12:35:26.691Z"},"accession":"S-EPMC7340656","cross_references":{"pubmed":["31983048"],"doi":["10.1007/s12975-019-00777-w"]}}